• Mashup Score: 4

    Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.

    Tweet Tweets with this article
    • New #benchtobedside article out today in Cell featuring #tazemetostat: first #epigenetic therapeutic against solid #tumors https://t.co/IysncAqDLl

  • Mashup Score: 1

    The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download…

    Tweet Tweets with this article
    • In the latest issue of Cell: a #benchtobedside on the treatment of antidepressant-resistant symptoms of #depression via #esketamine or #spravato https://t.co/AKIrShIYrJ

  • Mashup Score: 3

    Ervebo is the first licensed vaccine for prevention of Ebola virus disease. The vaccine, originally developed by the Public Health Agency of Canada, is delivered in a single 1 mL dose and has been delivered to >200,000 people in an ongoing 2018–2020 outbreak of disease. To view this Bench to Bedside, open or download the PDF.

    Tweet Tweets with this article
    • In the latest issue: a #benchtobedside on #ervebo, the first licensed vaccine for the prevention of #ebola https://t.co/2ihvtTvFFt

  • Mashup Score: 1

    VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity,…

    Tweet Tweets with this article
    • In the latest issue: new #benchtobedside: #brolucizumab directly inhibits #VEGF-A function, improving visual outcomes https://t.co/2nfR4K9iFN